bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per… (More)
  • table 1
Is this relevant?
Review
2017
Review
2017
Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca alkaloids, and proteasome/angiogenesis… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Mantle-cell lymphoma (MCL) is a mature B-cell lymphoma with an aggressive course and generally poor prognosis. Conventional… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Bortezomib therapy has proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM); however… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2004
Review
2004
The dipeptide boronic acid analogue VELCADE (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective… (More)
Is this relevant?